Many Bio-Pharma partnerships are currently focused on the development of vaccines and cures for patients with lung diseases, including long Covid19. This is the time to be specific and strategic with designing your trials and planning your resources.
IAG team and collaborators recorded this live webinar, designed for the drug developers focused on the lung diseases.
Key discussions points:
- Overview of clinical and imaging features of patients with lung diseases;
- Imaging in the drug trials of Covid19 and lung diseases;
- Imaging biomarkers for drugs in development;
- AI and modern infrastructure in relevance to these drug trials.
The session will begin with a joined talk by Dr. Faiq Shaikh, IAG’s member of scientific advisory board and Dr. Michael Andersen, IAG’s member of Scientific Advisory Board and Chairman of the Danish Lung Radiology Society, followed by a live Q&A with the audience.
About the Webinar:
This webinar is organized by IAG, Image Analysis Group
IAG’s imaging experts are sharing their knowledge on how imaging, AI and modern trial infrastructure can support drug development for lung diseases, specifically for Covid19 and long covid. The webinar will cover the use of X-ray, CT, PET, immunoPET based imaging endpoints and their relevance in supporting understanding of the efficacy and safety novel therapeutic agents.
About Dr. Faiq Shaikh:
Dr. Faiq Shaikh is IAG’s Head of Research & Enterprise. His background is in medical imaging and informatics. He is a physician with deep expertise in the use of molecular imaging, novel tracers and radiomics in clinical studies. Faiq is closely working with the world-class academic centres, biotechnology and pharmaceutical companies bringing predictive analytics and AI-based outcomes measures to drug development and clinical decision making.
About Dr. Michael Brun Andersen:
Dr. Andresen is a IAG’s Scientific Advisory Board and Chairman of the Danish Lung Radiology Society, expert in imaging and AI for lung diseases.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin